Quick Answer
Alzamend Neuro, Inc. reported Stockholders Equity of $3.97 million for fiscal year 2025.
Alzamend Neuro, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $3.97M | +253.0% |
| 2024 | -$2.59M | -185.2% |
| 2023 | $3.05M | -77.2% |
| 2022 | $13.35M | +563.3% |
| 2021 | $2.01M | +145.0% |
| 2020 | $821.7K | +159.3% |
| 2019 | $316.9K | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| October 31, 2025 | $4.37M | +16.6% | -18.1% |
| July 31, 2025 | $5.34M | +540.8% | +34.7% |
| April 30, 2025 | $3.97M | +253.0% | +15.0% |
| January 31, 2025 | $3.45M | +180.9% | -8.1% |
| October 31, 2024 | $3.75M | +239.9% | +409.6% |
| July 31, 2024 | -$1.21M | -974.0% | +53.3% |
| April 30, 2024 | -$2.59M | -185.2% | +39.2% |
| January 31, 2024 | -$4.26M | -172.8% | -58.9% |
- Alzamend Neuro, Inc. showed an increase of +253.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Alzamend Neuro, Inc.’s stockholders equity has grown by 1152.1% (from $316.9 thousand to $3.97 million).
- The most recent figure is from Alzamend Neuro, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on July 22, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: